These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 19544453)
21. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Mao XG; Hütt-Cabezas M; Orr BA; Weingart M; Taylor I; Rajan AK; Odia Y; Kahlert U; Maciaczyk J; Nikkhah G; Eberhart CG; Raabe EH Oncotarget; 2013 Jul; 4(7):1050-64. PubMed ID: 23846349 [TBL] [Abstract][Full Text] [Related]
22. EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Wang SD; Rath P; Lal B; Richard JP; Li Y; Goodwin CR; Laterra J; Xia S Oncogene; 2012 Dec; 31(50):5132-43. PubMed ID: 22310282 [TBL] [Abstract][Full Text] [Related]
23. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. deCarvalho AC; Nelson K; Lemke N; Lehman NL; Arbab AS; Kalkanis S; Mikkelsen T Stem Cells; 2010 Feb; 28(2):181-90. PubMed ID: 19937755 [TBL] [Abstract][Full Text] [Related]
24. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations. Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030 [TBL] [Abstract][Full Text] [Related]
25. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830 [TBL] [Abstract][Full Text] [Related]
26. ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics. Xu Q; Hu C; Zhu Y; Wang K; Lal B; Li L; Tang J; Wei S; Huang G; Xia S; Lv S; Laterra J; Jiang Y; Li Y Cancer Lett; 2020 Jul; 482():126-135. PubMed ID: 31954770 [TBL] [Abstract][Full Text] [Related]
27. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. Bijangi-Vishehsaraei K; Reza Saadatzadeh M; Wang H; Nguyen A; Kamocka MM; Cai W; Cohen-Gadol AA; Halum SL; Sarkaria JN; Pollok KE; Safa AR J Neurosurg; 2017 Dec; 127(6):1219-1230. PubMed ID: 28059653 [TBL] [Abstract][Full Text] [Related]
29. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related]
30. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis. Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119 [TBL] [Abstract][Full Text] [Related]
31. Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells. Lopez-Bertoni H; Lal B; Michelson N; Guerrero-Cázares H; Quiñones-Hinojosa A; Li Y; Laterra J Oncogene; 2016 Sep; 35(37):4903-13. PubMed ID: 26898758 [TBL] [Abstract][Full Text] [Related]
32. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component. Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191 [TBL] [Abstract][Full Text] [Related]
33. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830 [TBL] [Abstract][Full Text] [Related]
34. From the Cover: Neutralization of terminal differentiation in gliomagenesis. Hu J; Ho AL; Yuan L; Hu B; Hua S; Hwang SS; Zhang J; Hu T; Zheng H; Gan B; Wu G; Wang YA; Chin L; DePinho RA Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14520-7. PubMed ID: 23918370 [TBL] [Abstract][Full Text] [Related]
35. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Spina R; Voss DM; Asnaghi L; Sloan A; Bar EE Oncotarget; 2016 Jan; 7(1):459-72. PubMed ID: 26575950 [TBL] [Abstract][Full Text] [Related]
36. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Staberg M; Michaelsen SR; Rasmussen RD; Villingshøj M; Poulsen HS; Hamerlik P Cell Oncol (Dordr); 2017 Feb; 40(1):21-32. PubMed ID: 27766591 [TBL] [Abstract][Full Text] [Related]